P331 analysis of the clinical and therapeutic characteristics of patients admitted to the heart failure clinic in the period april–september 2022. organized by the anmco area cardio reno metabolica

Abstract In recent years, the pharmacological treatment of HFrEF has undergone considerable development. Two pharmacological classes in particular have been shown to significantly reduce cardiovascular events and hospitalizations: ARNI and SGLT2i. The objective of this observational study was to provide "real word" data on the effective use of these drugs, the efficacy, safety and tolerability of their simultaneous administration. We analyzed 82 patients admitted to our clinic over a period of 6 months and reported their clinical characteristics and the effective therapies administered. The data of 82 patients, 64% male, with an average age of 70.5 years were analysed. 49% with ischemic heart disease, 54% hypertension and 31% type 2 diabetes mellitus. Of these, 47.5% with HFrEF, 21% with HFmrEF, and the remaining 30% with HFpEF. At the time of visit, 19.5% of patients had a GFR <59 mL/min/1.73m2. 31% of the patients were in NYHA Class III. We then analyzed the drug therapies provided. Assuming that a very high percentage of patients were taking beta blockers and MRA (91% and 79% respectively), we found that about 72% of patients were on concomitant therapy with a renin angiotensin system inhibitor (51% ARNI, 21% ACEI/ARBs). Among the 51% of patients in ARNI, as many as 32% took the minimum dose of the drug (24/26mg bid), 11% the intermediate dose (49/51mg bid) and only the 8% the maximum recommended dosage (97/103 mg bid). In the group of patients with HFrEF, 10% were not on ARNI therapy or this drug had been discontinued during the follow–up (92% for hypotension, 8% for ARF on IRC). As for gliflozines, 46% of the patients analyzed were on SGLT2i therapy (and of these, approximately 70% had HFrEF). 30% of the total patients were in concomitant therapy with ARNi and SGLT2i (62% of patients affected by HFrEF). Conclusions most of our outpatients are affected by HFrEF, they benefit from the best pharmacological strategy recommended by the most recent international guidelines . The simultaneous administration of ARNI and SGLT2i is not burdened by significant adverse events. None of our patients discontinued SGLT2i therapy since there were no adverse effects related to drug administration.